Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy

Background— Extent and severity of myocardial ischemia are determinants of risk for patients with coronary artery disease, and ischemia reduction is an important therapeutic goal. The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) nuclear substudy compared the effectiveness of percutaneous coronary intervention (PCI) for ischemia reduction added to optimal medical therapy (OMT) with the use of myocardial perfusion single photon emission computed tomography (MPS). Methods and Results— Of the 2287 COURAGE patients, 314 were enrolled in this substudy of serial rest/stress MPS performed before treatment and 6 to 18 months (mean=374±50 days) after randomization using paired exercise (n=84) or vasodilator stress (n=230). A blinded core laboratory analyzed quantitative MPS measures of percent ischemic myocardium. Moderate to severe ischemia encumbered ≥10% myocardium. The primary end point was ≥5% reduction in ischemic myocardium at follow-up. Treatment groups had similar baseline characteristics. At follow-up, the reduction in ischemic myocardium was greater with PCI+OMT (−2.7%; 95% confidence interval, −1.7%, −3.8%) than with OMT (−0.5%; 95% confidence interval, −1.6%, 0.6%; P<0.0001). More PCI+OMT patients exhibited significant ischemia reduction (33% versus 19%; P=0.0004), especially patients with moderate to severe pretreatment ischemia (78% versus 52%; P=0.007). Patients with ischemia reduction had lower unadjusted risk for death or myocardial infarction (P=0.037 [risk-adjusted P=0.26]), particularly if baseline ischemia was moderate to severe (P=0.001 [risk-adjusted P=0.08]). Death or myocardial infarction rates ranged from 0% to 39% for patients with no residual ischemia to ≥10% residual ischemia on follow-up MPS (P=0.002 [risk-adjusted P=0.09]). Conclusions— In COURAGE patients who underwent serial MPS, adding PCI to OMT resulted in greater reduction in ischemia compared with OMT alone. Our findings suggest a treatment target of ≥5% ischemia reduction with OMT with or without coronary revascularization.

[1]  G. Germano,et al.  Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy , 2009 .

[2]  A. Gould,et al.  Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. , 2007, Clinical therapeutics.

[3]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[4]  L. Shaw,et al.  An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. , 2006, Journal of the American College of Cardiology.

[5]  D. Berman,et al.  Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424 , 2006, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[6]  G. Hung,et al.  Worsening of left ventricular ejection fraction induced by dipyridamole on Tl-201 gated myocardial perfusion imaging predicts significant coronary artery disease. , 2006, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[7]  A. Iskandrian,et al.  Gated SPECT perfusion imaging for the simultaneous assessment of myocardial perfusion and ventricular function in the BARI 2D trial: An initial report from the Nuclear Core Laboratory , 2006, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[8]  D. Berman,et al.  Automated quantification of myocardial perfusion SPECT using simplified normal limits , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[9]  Daniel S. Berman,et al.  Prognostic validation of a 17-segment score derived from a 20-segment score for myocardial perfusion spect interpretation , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[10]  L. Shaw,et al.  Prognostic value of gated myocardial perfusion SPECT , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[11]  Abrar H. Shah,et al.  Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial. , 2003, Journal of the American College of Cardiology.

[12]  D. Berman,et al.  Comparison of the Short‐Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery Disease Undergoing Stress Myocardial Perfusion Single Photon Emission Computed Tomography , 2003, Circulation.

[13]  D. Berman,et al.  Serial changes on quantitative myocardial perfusion SPECT in patients undergoing revascularization or conservative therapy , 2001, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[14]  L. Martín-Jadraque,et al.  Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. , 2000, Journal of the American College of Cardiology.

[15]  D. Berman,et al.  The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia. Economics of Noninvasive Diagnosis (END) Multicenter Study Group. , 1999, Journal of the American College of Cardiology.

[16]  R. Hall,et al.  Randomized, double-blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise-induced myocardial stunning. , 1998, Circulation.

[17]  D. Berman,et al.  Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. , 1998, Circulation.

[18]  P. Hartigan,et al.  Evaluation of exercise thallium scintigraphy versus exercise electrocardiography in predicting survival outcomes and morbid cardiac events in patients with single- and double-vessel disease. Findings from the Angioplasty Compared to Medicine (ACME) Study. , 1997, Journal of the American College of Cardiology.

[19]  V. Fuster,et al.  27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. , 1996, Journal of the American College of Cardiology.

[20]  R. Califf,et al.  27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. , 1996, Journal of the American College of Cardiology.

[21]  D. Berman,et al.  Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. , 1996, Circulation.

[22]  D. Berman,et al.  Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  D. Berman,et al.  Quantitative severity of stress thallium-201 myocardial perfusion single-photon emission computed tomography defects in one-vessel coronary artery disease. , 1993, The American journal of cardiology.